TEZSPIRE Subcutaneous Injection 210mg Specific use-results study (Long term) in patients with Bronchial asthma.
Bronchial asthma (only the patients with severe or intractable bronchial asthma which could not be controlled with the existing therapy)
n/a - n/a
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Nov 2023 by AstraZeneca
No locations available